Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 809 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo vehicle Clear all
Recruiting Phase 3 Interventional

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

NCT05555589
View directory record Official record
Conditions
Neurotrophic Keratopathy
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
29
States / cities
Laguna Hills, California • Loma Linda, California • Colorado Springs, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

NCT00990613
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon IR, Dimebon Transdermal
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Sep 15, 2026, 4:15 PM EDT
Active, not recruiting Phase 3 Interventional

Study of OT-101 in Treating Myopia

NCT04770610
View directory record Official record
Conditions
Myopia, Progressive
Interventions
OT-101 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Ocumension (Hong Kong) Limited
Other
Eligibility
3 Years to 15 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 15, 2026, 4:15 PM EDT
Recruiting Phase 3 Interventional

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

NCT04451330
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study to Treat Bacterial Vaginosis

NCT01621399
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Product 55394, Placebo Vehicle (non-treatment)
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Mesa, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 15, 2026, 4:15 PM EDT
Not listed Phase 3 Interventional

TDT 067 Onychomycosis Study

NCT01145807
View directory record Official record
Conditions
Onychomycosis
Interventions
TDT067, Placebo, Transfersome
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Albequerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

NCT04462536
View directory record Official record
Conditions
Stroke, Acute
Interventions
Placebo, Nerinetide
Drug
Lead sponsor
NoNO Inc.
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • Torrance, California • Englewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia

NCT02516306
View directory record Official record
Conditions
Presbyopia
Interventions
EV06 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Encore Vision, Inc.
Industry
Eligibility
45 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Artesia, California • Mission Hills, California • Washington, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

NCT02247804
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
56
States / cities
Phoenix, Arizona • Glendale, California • Irvine, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 15, 2026, 4:15 PM EDT
Suspended Phase 2 Interventional

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

NCT05067257
View directory record Official record
Conditions
Pain, Intractable, Pain Cancer, Pain
Interventions
Resiniferatoxin, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
La Jolla, California • Gainesville, Florida • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

NCT03200912
View directory record Official record
Conditions
ACTINIC KERATOSIS
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Oceanside, California • Denver, Colorado • Aventura, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back

NCT00783965
View directory record Official record
Conditions
Skin Carcinoma
Interventions
tazarotene, placebo
Drug · Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
3
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

NCT04004507
View directory record Official record
Conditions
Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443820
View directory record Official record
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
20
States / cities
Novato, California • Northglenn, Colorado • Melbourne, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts

NCT03532776
View directory record Official record
Conditions
External Anogenital Warts
Interventions
Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, Placebo Gel
Drug
Lead sponsor
Dermax SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 4 Interventional

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

NCT00121381
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 2Phase 3 Interventional

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

NCT05397665
View directory record Official record
Conditions
Hereditary Neuropathy Caused by SORD Deficiency
Interventions
AT-007, Placebo
Drug
Lead sponsor
Applied Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Coral Gables, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

NCT00624351
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced Sep 15, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

NCT00766337
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Sirolimus in combination with ranibizumab, Placebo in combination with ranibizumab
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Cantharidin Application in Molluscum Patients

NCT03377803
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
15
States / cities
Bakersfield, California • San Diego, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Hydrocortisone in Endotoxemia in Normal Volunteers

NCT01064986
View directory record Official record
Conditions
Infections
Interventions
Endotoxin, Lipopolysaccharide, LPS, Endotoxin, Lipopolysaccharide, LPS /Epinephrine, Placebo, Hydrocortisone
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pimecrolimus Cream for Oral Lichen Planus

NCT00297037
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Pimecrolimus 1% cream
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Sep 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears

NCT02420353
View directory record Official record
Conditions
Rupture of Anterior Cruciate Ligament
Interventions
Somatropin, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Sep 15, 2026, 4:15 PM EDT